ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Amgen and Qilu Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AmgenQilu Pharmaceutical
studies on the registry1,088218
open to participants now50135
phase 3 studies under way5053
reach primary completion within a year3549
programswith a study of their own in two years2471

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAmgenQilu Pharmaceutical
Phase 1

Amgen: 8 of its 24 programs at phase 1

  1. AMG 691phase 1
  2. AMG 127phase 1
  3. etakafusp alfaphase 1
  4. Pan-KRAS Inhibitor AMG 410phase 1
  5. tambotatug pelitecanphase 1

and 3 more — sign in to see them all

33%

Qilu Pharmaceutical: 23 of its 71 programs at phase 1

  1. apripitant and palonosetron injectable emulsionphase 1
  2. follitropin alfaphase 1
  3. Meropenem-Pralubactamphase 1
  4. QL2302phase 1
  5. QLF4113phase 1

and 18 more — sign in to see them all

32%
Phase 2

Amgen: 1 of its 24 programs at phase 2

  1. AMG 732phase 2
4%

Qilu Pharmaceutical: 14 of its 71 programs at phase 2

  1. QLS1410phase 2
  2. QLS12010phase 2
  3. KRAS G12D Inhibitor QLC1101phase 2
  4. QLH12016phase 2
  5. QLC1401phase 2

and 9 more — sign in to see them all

20%
Phase 3

Amgen: 7 of its 24 programs at phase 3

  1. maridebart cafraglutidephase 3
  2. tarlatamabphase 3
  3. xaluritamigphase 3
  4. sotorasibphase 3
  5. olpasiranphase 3

and 2 more — sign in to see them all

29%

Qilu Pharmaceutical: 32 of its 71 programs at phase 3

  1. Iparomlimab/Tuvonralimabphase 3
  2. QLC5508phase 3
  3. Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905phase 3
  4. QL2107phase 3
  5. QLC7401phase 3

and 27 more — sign in to see them all

45%
Approved, new studies

Amgen: 8 of its 24 programs at approved, new studies

  1. inebilizumabapproved, new study
  2. blinatumomabapproved, new study
  3. apremilastapproved, new study
  4. evolocumabapproved, new study
  5. romiplostimapproved, new study

and 3 more — sign in to see them all

33%

Qilu Pharmaceutical: 2 of its 71 programs at approved, new studies

  1. Dimethyl Fumarate Enteric-coated Capsulesapproved, new study
  2. Tafamidis Meglumine Soft Capsulesapproved, new study
3%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Amgen12 readouts · 2 phase 3

Amgen, Nov ’26: 1 program whose next study reaches primary completion

  1. maridebart cafraglutidephase 3 · Nov 18 · NCT07523711

Amgen, Dec ’26: 1 program whose next study reaches primary completion

  1. sotorasibphase 3 · Dec 17 · NCT04185883

Amgen, Jan ’27: 3 programs whose next study reaches primary completion

  1. AMG 732phase 2 · Jan 6 · NCT06401044
  2. apremilastapproved, new study · Jan 10 · NCT07908641
  3. romosozumabapproved, new study · Jan 14 · NCT07811999

Amgen, Feb ’27: 1 program whose next study reaches primary completion

  1. xaluritamigphase 3 · Feb 17 · NCT06613100

Amgen, Mar ’27: 1 program whose next study reaches primary completion

  1. AMG 691phase 1 · Mar 17 · NCT07745907

Amgen, Apr ’27: 2 programs whose next study reaches primary completion

  1. inebilizumabapproved, new study · Apr 13 · NCT05549258
  2. tarlatamabphase 3 · Apr 24 · NCT06598306

Amgen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. evolocumabapproved, new study · May 29 · NCT05284747
·

Amgen, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. afliberceptphase 3 · Jul 31 · NCT07614776
··

Amgen, Oct ’27: 1 program whose next study reaches primary completion

  1. AMG 127phase 1 · Oct 2 · NCT07590193
Qilu Pharmaceutical36 readouts · 13 phase 3

Qilu Pharmaceutical, Nov ’26: 2 programs whose next study reaches primary completion

  1. apripitant and palonosetron injectable emulsionphase 1 · Nov 0 · NCT07817004
  2. QLS1304phase 2 · Nov 0 · NCT06823609

Qilu Pharmaceutical, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3

  1. Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905phase 3 · Dec 0 · NCT06942767
  2. pralurbactamphase 3 · Dec 0 · NCT07089186
  3. QL1207Hphase 3 · Dec 0 · NCT07489586
  4. QL2107phase 3 · Dec 0 · NCT06754644
  5. QLG1091phase 3 · Dec 0 · NCT07487103

and 4 more — sign in to see them all

Qilu Pharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. QL1206phase 3 · Jan 0 · NCT07062978
  2. QLS1510phase 1 · Jan 30 · NCT07760077

Qilu Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. QLC1401phase 2 · Feb 0 · NCT07173556

Qilu Pharmaceutical, Mar ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. QLH2405phase 1 · Mar 0 · NCT07489599
  2. QLM3003phase 3 · Mar 0 · NCT06880276

Qilu Pharmaceutical, Apr ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-HER2 Monoclonal Antibody QL1209phase 3 · Apr 0 · NCT07861139
  2. Platinum Compoundsphase 2 · Apr 0 · NCT07453394
  3. QLS1209phase 1 · Apr 0 · NCT06872580
  4. QLS5132phase 3 · Apr 0 · NCT07453394
  5. QL0911phase 3 · Apr 30 · NCT06456528

Qilu Pharmaceutical, May ’27: 4 programs whose next study reaches primary completion, 4 in phase 3

  1. Anti-B7-H3 Antibody-drug Conjugate MHB088Cphase 3 · May 0 · NCT06954246
  2. daprodustatphase 3 · May 0 · NCT07300111
  3. QL2108phase 3 · May 0 · NCT06884891
  4. QLG2128phase 3 · May 0 · NCT06898060

Qilu Pharmaceutical, Jun ’27: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-TROP2 Antibody-drug Conjugate ESG401phase 3 · Jun 0 · NCT06732323
  2. Iparomlimab/Tuvonralimabphase 3 · Jun 0 · NCT07272590
  3. QL2401phase 2 · Jun 0 · NCT07620366
  4. QLC5513phase 2 · Jun 0 · NCT07272590
  5. QLS5308phase 1 · Jun 0 · NCT07462442

and 2 more — sign in to see them all

Qilu Pharmaceutical, Jul ’27: 1 program whose next study reaches primary completion

  1. QLS5133phase 2 · Jul 0 · NCT07061639

Qilu Pharmaceutical, Aug ’27: 1 program whose next study reaches primary completion

  1. QLS2406-1 injectionphase 1 · Aug 30 · NCT07937787
·

Qilu Pharmaceutical, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. QLC7401phase 3 · Oct 7 · NCT07444086
  2. QLS2312phase 1 · Oct 9 · NCT07861581
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Amgen

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 5

Qilu Pharmaceutical

New programs 6

Reached a new phase 2

  • QLS4131phase 3 · Nov 6 · Multiple Myeloma
  • QLS5132phase 3 · Oct 20 · Carcinoma, Ovarian Epithelial

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 24 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionAmgenQilu Pharmaceutical
Carcinoma, Non-Small-Cell Lungboth · compare here

Amgen in Carcinoma, Non-Small-Cell Lung: 5 programs

  1. sotorasibphase 3
  2. etakafusp alfaphase 1
  3. Pan-KRAS Inhibitor AMG 410phase 1
  4. tambotatug pelitecanphase 1
  5. romiplostimapproved, new study

Their studies: Amgen’s studies of Carcinoma, Non-Small-Cell Lung in search

Qilu Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 5 programs

  1. Iparomlimab/Tuvonralimabphase 3
  2. QL2107phase 3
  3. romiplostimphase 3
  4. KRAS G12D Inhibitor QLC1101phase 2
  5. Platinum Compoundsphase 2

Their studies: Qilu Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Small Cell Lung Carcinomaboth · compare here

Amgen in Small Cell Lung Carcinoma: 4 programs

  1. tarlatamabphase 3
  2. etakafusp alfaphase 1
  3. tambotatug pelitecanphase 1
  4. Zocilurtatug Pelitecanphase 1

Their studies: Amgen’s studies of Small Cell Lung Carcinoma in search

Prostatic Neoplasmsboth · compare here

Amgen in Prostatic Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. xaluritamigphase 3

Their studies: Amgen’s studies of Prostatic Neoplasms in search

Qilu Pharmaceutical in Prostatic Neoplasms: 5 programs

  1. QLC5508phase 3
  2. QLG1080phase 3
  3. QLH12016phase 2
  4. QLF4113phase 1
  5. QLS2401phase 1

Their studies: Qilu Pharmaceutical’s studies of Prostatic Neoplasms in search

Colorectal Neoplasmsboth · compare here

Amgen in Colorectal Neoplasms: 2 programs

  1. sotorasibphase 3
  2. afliberceptphase 3

Their studies: Amgen’s studies of Colorectal Neoplasms in search

Qilu Pharmaceutical in Colorectal Neoplasms: 3 programs

  1. Iparomlimab/Tuvonralimabphase 3
  2. QL1203phase 3
  3. QLS5316phase 1

Their studies: Qilu Pharmaceutical’s studies of Colorectal Neoplasms in search

Lupus Erythematosus, Systemicboth · compare here

Amgen in Lupus Erythematosus, Systemic: 1 program

  1. inebilizumabapproved, new study

Their studies: Amgen’s studies of Lupus Erythematosus, Systemic in search

Qilu Pharmaceutical in Lupus Erythematosus, Systemic: 3 programs

  1. QLS4131phase 3
  2. QLS2404phase 1
  3. QLS2416phase 1

Their studies: Qilu Pharmaceutical’s studies of Lupus Erythematosus, Systemic in search

Neoplasmsboth · compare here

Amgen in Neoplasms: 2 programs

  1. tarlatamabphase 3
  2. teprotumumabapproved, new study

Their studies: Amgen’s studies of Neoplasms in search

Qilu Pharmaceutical in Neoplasms: 2 programs

  1. QL2107phase 3
  2. QL2109phase 3

Their studies: Qilu Pharmaceutical’s studies of Neoplasms in search

Diabetes Mellitus, Type 2both · compare here

Amgen in Diabetes Mellitus, Type 2: 2 programs

  1. maridebart cafraglutidephase 3
  2. AMG 127phase 1

Their studies: Amgen’s studies of Diabetes Mellitus, Type 2 in search

Qilu Pharmaceutical in Diabetes Mellitus, Type 2: 1 program

  1. QLG1091phase 3

Their studies: Qilu Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Hypercholesterolemiaboth · compare here

Amgen in Hypercholesterolemia: 1 program

  1. evolocumabapproved, new study

Their studies: Amgen’s studies of Hypercholesterolemia in search

Qilu Pharmaceutical in Hypercholesterolemia: 2 programs

  1. QLC7401phase 3
  2. RBD7022phase 1

Their studies: Qilu Pharmaceutical’s studies of Hypercholesterolemia in search

Osteoporosisboth · compare here

Amgen in Osteoporosis: 1 program

  1. romosozumabapproved, new study

Their studies: Amgen’s studies of Osteoporosis in search

Qilu Pharmaceutical in Osteoporosis: 2 programs

  1. QL1206phase 3
  2. QLG2128phase 3

Their studies: Qilu Pharmaceutical’s studies of Osteoporosis in search

Purpura, Thrombocytopenic, Idiopathicboth · compare here

Amgen in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. romiplostimapproved, new study

Their studies: Amgen’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Qilu Pharmaceutical in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. QL0911phase 3
  2. romiplostimphase 3

Their studies: Qilu Pharmaceutical’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Anemia, Aplasticboth · compare here

Amgen in Anemia, Aplastic: 1 program

  1. romiplostimapproved, new study

Their studies: Amgen’s studies of Anemia, Aplastic in search

Qilu Pharmaceutical in Anemia, Aplastic: 1 program

  1. romiplostimphase 3

Their studies: Qilu Pharmaceutical’s studies of Anemia, Aplastic in search

Arthritis, Rheumatoidboth · compare here

Amgen in Arthritis, Rheumatoid: 1 program

  1. dazodalibepphase 3

Their studies: Amgen’s studies of Arthritis, Rheumatoid in search

Qilu Pharmaceutical in Arthritis, Rheumatoid: 1 program

  1. QLS12010phase 2

Their studies: Qilu Pharmaceutical’s studies of Arthritis, Rheumatoid in search

Show all 24

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Amgen 17 of 24 · Qilu Pharmaceutical 18 of 71 programs (34 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.